Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
Part of Lungs & breathing clinical trials.
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IPF (idiopathic pulmonary fibrosis) or PPF (progressive pulmonary fibrosis).
- You are about to start a new anti-fibrotic medication (either nintedanib or pirfenidone).
- You are 18 years old or older.
- You are able to make your own decisions and give informed consent.
- You have not taken anti-fibrotic medication before.
- You have not lost more than 10% of your body weight in the last 3-6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients and doctors decide on treatment for pulmonary fibrosis. It aims to understand the impact of side effects from antifibrotic medicines on treatment choices.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.